PIK3CG and keloid: Targeting the PI3K/AKT/mTOR pathway presents a promising therapeutic approach for keloid treatment, given its central role in controlling fibroblast proliferation, migration, survival, and myofibroblast differentiation, processes fundamental to keloid pathogenesis (Kim and Kim, 2024).